What is myo-inositol?
Myo-inositol is a naturally occurring carbohydrate (a cyclohexane polyol) found in high concentrations in fruits, grains, legumes, and nuts. Despite being sometimes called "vitamin B8," it is not a true vitamin as the body can synthesise it from glucose. It exists in nine stereoisomeric forms; myo-inositol is the most abundant in human tissues, comprising ~95% of total free inositol in plasma.
The second most physiologically relevant isomer is D-chiro inositol (DCI), found primarily in intracellular signalling compartments. The body converts myo-inositol to DCI via an insulin-dependent epimerase enzyme — a conversion rate that is dysregulated in type 2 diabetes and PCOS.
The PCOS connection — India's hidden epidemic
PCOS (polycystic ovary syndrome) affects an estimated 20–25% of Indian women of reproductive age — among the highest prevalence globally, likely driven by South Asian insulin resistance genetics, high-carbohydrate dietary patterns, and metabolic syndrome overlap. PCOS features include irregular cycles, elevated androgens (testosterone, DHEA-S), impaired ovulation, and insulin resistance in 60–80% of cases.
Inositol deficiency plays a direct mechanistic role. The ovary relies on myo-inositol for FSH (follicle-stimulating hormone) signal transduction. When ovarian myo-inositol is deficient — a hallmark finding in PCOS — follicle development and ovulation are impaired. Supplementation directly addresses this pathophysiology.
A 2019 meta-analysis (Unfer et al.) of 21 RCTs in PCOS found myo-inositol significantly improved: menstrual cycle regularity, ovulation rate, LH/FSH ratio, free androgen index, fasting insulin, and HOMA-IR. It is recommended by the International Evidence-Based Guideline for the Assessment and Management of PCOS (2023 update) as a safe and effective adjunctive treatment.
Mechanism of action
Myo-inositol operates through several complementary pathways:
- Insulin second messenger: After insulin binds its receptor, it triggers release of inositolphosphoglycan (IPG) messengers derived from phosphatidylinositol. These IPGs activate enzymes (including pyruvate dehydrogenase phosphatase) that are critical for glucose oxidation and GLUT4 translocation to the cell membrane for glucose uptake.
- GLUT4 activation: By improving the downstream insulin signalling cascade, myo-inositol increases GLUT4 membrane expression, enabling muscle and fat cells to take up glucose more efficiently — directly improving insulin resistance.
- GLP-1 stimulation: Inositol promotes secretion of GLP-1 (glucagon-like peptide-1) from intestinal L-cells, enhancing glucose-dependent insulin release and slowing gastric emptying. This is the same pathway (though weaker) as semaglutide (Ozempic).
- FSH signalling in the ovary: Myo-inositol mediates FSH signal transduction in granulosa cells. Adequate ovarian inositol levels are required for normal follicle maturation, oocyte quality, and ovulation — explaining its profound PCOS benefits.
The 40:1 ratio explained
In plasma, myo-inositol and DCI exist at a 40:1 ratio under physiological conditions. This ratio is tissue-specific: the ovary needs high myo-inositol relative to DCI for optimal FSH signalling. The kidney converts excess myo-inositol to DCI to regulate glucose; women with PCOS have enhanced renal epimerisation, depleting systemic myo-inositol.
Taking DCI alone — or in ratios skewed toward DCI — paradoxically impairs oocyte quality and worsens PCOS outcomes in some studies. A landmark study by Unfer et al. (2017) showed that while DCI improves androgen and insulin parameters, it reduces FSH sensitivity in granulosa cells. The 40:1 myo:DCI combination product addresses both insulin sensitivity AND ovarian function simultaneously.
Clinical evidence summary
| Outcome | Effect Size | Evidence Quality |
|---|---|---|
| Menstrual cycle restoration (PCOS) | ~65–80% of women | Multiple RCTs — Strong |
| LH/FSH ratio normalisation | Significant reduction | Multiple RCTs — Strong |
| Fasting insulin reduction | 15–25% reduction | Multiple RCTs — Strong |
| HOMA-IR improvement | 20–30% reduction | Multiple RCTs — Strong |
| Free testosterone reduction | Significant | Multiple RCTs — Moderate-Strong |
| HbA1c reduction (T2DM) | 0.4–0.7% | Limited RCTs — Moderate |
| Triglyceride reduction | 15–20% | Multiple RCTs — Moderate |
| Ovulation rate (IVF outcomes) | Improved oocyte quality | RCTs — Moderate-Strong |
| Anxiety / mood (off-label) | Modest benefit at 12–18g/day | Small RCTs — Emerging |
Dosing protocol
For PCOS (primary indication): 2000 mg myo-inositol twice daily (4000 mg/day total), combined with 50–100 mg D-chiro inositol (to maintain 40:1 ratio). Often combined with 200–400 mcg folic acid/methylfolate. Most European PCOS protocols and the Inofolic series of products use this dose. Take with water, morning and evening, ideally before meals.
For general metabolic/insulin resistance: 2000 mg myo-inositol twice daily (4000 mg/day). Can start at 1000 mg twice daily for 2 weeks.
For anxiety/mood (off-label, higher dose protocol): 12–18g/day in divided doses — this is a separate use-case with distinct evidence from OCD and panic disorder research.
Timeline: Cycle regularity improvements typically seen at 3–4 months. Hormonal marker improvements (LH, androgens, insulin) measurable at 6–12 weeks. For fertility purposes, 3–6 months of pre-conception use is typically recommended.
Safety profile
Myo-inositol has an excellent safety profile. It is classified as generally recognised as safe (GRAS) as a food ingredient. At doses up to 12g/day, the only commonly reported side effect is mild GI discomfort (nausea, loose stools) at initiation, which resolves with dose splitting. No serious adverse events have been reported in clinical trials. It is safe in pregnancy (it reduces gestational diabetes risk when taken pre-conception and in first trimester). It does not cause hypoglycaemia when used alone.
India-specific context
PCOS is dramatically under-diagnosed in India — most women experience symptoms for years before formal diagnosis. Indian dietary patterns (high refined carbohydrates, low fibre) combined with South Asian insulin resistance genetics create an ideal environment for inositol deficiency. Myo-inositol is available in India as a nutraceutical powder or capsule; quality varies. Look for products that specify myo-inositol content (not just "inositol") and ideally the 40:1 myo:DCI combination. Monthly cost for 4g/day: ₹800–₹1800 depending on brand and format.
- Myo-inositol 4000 mg/day (in 40:1 ratio with DCI)
- Methylfolate 400 mcg/day (particularly important for fertility)
- Vitamin D3 2000–4000 IU/day (deficiency is near-universal in Indian PCOS)
- Omega-3 1–2g EPA+DHA (reduces ovarian inflammation)
- Optional: Berberine 500 mg twice daily (additive insulin-sensitising effect)
Frequently asked questions
What is the correct myo-inositol dose for PCOS in India?
4000 mg/day total myo-inositol, split into two 2000 mg doses, combined with 100 mg D-chiro inositol (40:1 ratio). Add methylfolate 400 mcg if trying to conceive. Effects on cycle regularity appear at 3–6 months.
What is the myo-inositol to D-chiro inositol ratio and why does it matter?
The 40:1 ratio reflects normal plasma physiology. Women with PCOS over-convert myo-inositol to DCI, depleting ovarian myo-inositol needed for FSH signalling. Using 40:1 combination products addresses both ovarian function and insulin resistance simultaneously. Pure DCI alone can impair oocyte quality.
Does myo-inositol help with insulin resistance?
Yes — it is a direct second messenger in insulin signalling, required for GLUT4 glucose transporter activation. Studies show 15–25% reduction in fasting insulin and 20–30% improvement in HOMA-IR in PCOS patients. It also stimulates GLP-1, adding an incretin mechanism.
Can myo-inositol be combined with metformin?
Yes — the combination is synergistic. Metformin reduces hepatic glucose production; myo-inositol improves peripheral insulin signalling and ovarian function. Multiple RCTs show better outcomes with the combination. This combination is used by some Indian endocrinologists for PCOS with insulin resistance.